San Diego, California-based DexCom, Inc. (DXCM) is a medical technology company focused on continuous glucose monitoring (CGM ...

DexCom, Inc.'s growth is impressive but limited by its niche market, with my projected ceiling being ~$7.5bn in peak annual revenues. Despite positive Q4 2024 results, DexCom's stock is fairly valued, ...

Event context and recent share performance DexCom (DXCM) shares have been under pressure recently, with the stock down about 3% over the past month and 8.6% over the past 3 months, while the business ...

DexCom reported mixed Q2 results with an earnings beat, but revenue missed expectations. The company lowered its full-year revenue guidance. DexCom's steep valuation is only justifiable with sustained ...

Let’s dig into the relative performance of DexCom (NASDAQ:DXCM) and its peers as we unravel the now-completed Q4 patient ...

Over the last six months, DexCom’s shares have sunk to $62.07, producing a disappointing 6.4% loss - a stark contrast to the ...

Dexcom develops continuous glucose monitoring (CGM) devices. Diabetic patients use these to track their glucose levels in ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

We have excluded third-party attorney’s fees, costs, and expenses incurred by Dexcom exclusively in connection with Dexcom’s patent infringement litigation against Abbott Diabetes Care, Inc., as ...

Dexcom Share, a cradle device that will allow users to send data from a Dexcom continuous glucose monitor to multiple smartphones, has received 510(k) clearance from the FDA. The system is designed to ...